Skip to main content
Clinical Trials/NCT01323556
NCT01323556
Unknown
Phase 2

Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure

University Medicine Greifswald1 site in 1 country180 target enrollmentMarch 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Panic Disorder
Sponsor
University Medicine Greifswald
Enrollment
180
Locations
1
Primary Endpoint
Hamilton Anxiety Rating Scale (HARS)
Last Updated
15 years ago

Overview

Brief Summary

Investigation of mechanisms of exposure based learning by

  1. Investigating the effects of fear augmentation by interoceptive exposure during in vivo exposure
  2. Disentangling the effects of interoceptive exposure exercises in panic disorder

Detailed Description

The study aims on investigating the effect of fear augmentation during in-vivo exposure by adding interoceptive exposure (e.g., hyperventilation) in PD/AG patients. By comparing the fear augmentation group with the therapist-guided CBT exposure, and by measuring autonomic arousal during and between exposure sessions, it will be possible to study the mechanisms of exposure based learning. A second aim is to disentangle effects of specific interoceptive exposure exercises (e.g., respiratory vs. vestibular stimulation). Finally, by including patients without agoraphobic avoidance it will be possible to investigate whether interoceptive exposure alone will have any effect. This might open the door for early interventions for individuals after experiencing an initial panic attack to prevent the development of a severe panic disorder with agoraphobic avoidance.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
May 2012
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Medicine Greifswald

Eligibility Criteria

Inclusion Criteria

  • Age 18-65 years old
  • Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of panic disorder, panic disorder with agoraphobia OR initial panic attacks
  • CGI ≥ 4 (except persons with initial panic attacks)
  • Informed Consent

Exclusion Criteria

  • Acute suicidality
  • Current substance use disorder
  • Lifetime diagnosis of psychotic disorders, bipolar disorders, borderline personality disorders
  • Severe medical condition (chronic conditions)
  • Current psychotherapeutic or psychopharmacological treatment

Outcomes

Primary Outcomes

Hamilton Anxiety Rating Scale (HARS)

Time Frame: up to 32 weeks (follow up)

structured clinician rating assessing the severity of an anxiety disorder

Clinician Global Impression Scale (CGI)

Time Frame: up to 32 weeks (follow up)

clinician rating assessing the severity of panic disorder and agoraphobia

Panic and Agoraphobia Scale (PAS)

Time Frame: up to 32 weeks (follow up)

PAS is self-rating assessing panic disorder and agoraphobia severity with five factor analytic derived subscale scores (panic attacks, anticipatory anxiety, agoraphobic avoidance, health concerns, functional impairment) and a total score indicating the global severity. The questionnaire was specifically developed for monitoring changes during psychotherapy or psychopharmacological treatments.

Mobility Inventory

Time Frame: up to 32 weeks (follow up)

Self-rating assessing the extent of situational avoidance. The questionnaire comprises 27 situations that have to be evaluated in regard to frequency of avoidance, when alone or when accompanied.

Number of panic attacks

Time Frame: up to 32 weeks (follow up)

Number of panic attacks experienced during the last week is assessed.

Study Sites (1)

Loading locations...

Similar Trials